4th Global Meeting on Implementing New and Under-utilized Vaccines, 23-25 June 2010
Context
Participants at the meeting recognized the immense progress made in the field of new vaccines introduction including Hib, pneumo, rota and HPV vaccines since the last meeting in June 2009. The introduction of Hib vaccine globally has made big progress with 165/193 countries having already introduced nationwide, two countries with partial introductions and three countries planning introduction in 2010/11. Of particular note, following an extended decision-making process, India plans to introduce Hib vaccine in 5 States in 2010 and in 5 additional States thereafter.
Further key achievements since the last meeting:
- First procurement of pneumococcal vaccine under AMC concluded, first contracts established for 60 Million doses annually for 10 years as of 2012/13
- PCV10 and PCV13 potentially available in countries by Q4/2010
- Publication in December 2009 of the update to the rotavirus vaccine WHO Position Paper with the recommendation for global use of the vaccine
- CCL requirements for rotavirus vaccine improved with new presentations
- GAVI applications for rotavirus vaccine submitted by 8 African countries
- Gardasil™ (5/09) and Cervarix™ (7/09) WHO prequalified
- High-level advocacy of HPV vaccine in many countries
Continuing and new challenges:
- Hib:
- Other large countries have not yet introduced: Nigeria, Indonesia, China – 52% of the world's children do not yet have access to the vaccine
- Price reduction of pentavalent vaccine less than expected
- Recent pentavalent vaccine recall to be managed by countries and partners
- Regional impact of AEFI in Sri Lanka and Bhutan
- PCV:
- Plan to revise demand forecast following GAVI Board decisions
- Manage possible continued AMC eligibility of all 72 GAVI countries
- Supply constraints for 2010/11 necessitate supply allocation procedures
- Strain replacement – Review of changing Streptococcus pneumoniae epidemiology in July 10 meeting
- Rota
- Lower efficacy in high mortality countries, but high absolute number of severe GE episodes prevented
- PCV1 and 2 as adventitious agents led to suspension of use in several countries
- Risk to be down-prioritized vs. PCV if simultaneous introductions not supported by GAVI
- Demand for UNICEF procuring countries not yet established: Vaccine price unknown
- HPV
- Immunization partners to clarify position vis-à-vis time-limited donation programmes
- Price to be in the lower single digit range (USD/dose) to be cost-effective in most DC
- New delivery systems needed with additional delivery costs (approx. 3- 5 USD /girl)
- New approaches for vaccine coverage and impact monitoring to be piloted
By clicking on the following links, you will be able to view summaries of the opening plenary session, of the eight Work Groups, of the market place and of the panel session.
- Introductory session
- Workgroup 1. Pneumococcal and rotavirus vaccines, including surveillance and cost-effectiveness issues
- Workgroup 2. New vaccine introduction in lower middle income countries
- Workgroup 3. Planning and financing for immunization
- Workgroup 4. Introduction of more than one new vaccine at a time
- Workgroup 5. Impact of new vaccine introduction on immunization and health systems
- Workgroup 6. Vaccines of regional importance: typhoid and cholera
- Workgroup 7. Integrated approaches to vaccine-preventable disease control
- Workgroup 8. Data quality and surveillance - Is this as good as it gets? Can information on immunization be improved?
- Market Place Session
- Panel Discussion